暂无分享,去创建一个
Pierluigi Colli | Elisabetta Rocca | Gabriela Marinoschi | Hector Gomez | Alessandro Reali | Guillermo Lorenzo | G. Marinoschi | A. Reali | G. Lorenzo | P. Colli | E. Rocca | H. Gómez
[1] Ernesto A. B. F. Lima,et al. A hybrid ten-species phase-field model of tumor growth , 2014 .
[2] Alessandro Reali,et al. Computer simulations suggest that prostate enlargement due to benign prostatic hyperplasia mechanically impedes prostate cancer growth , 2019, Proceedings of the National Academy of Sciences.
[3] M Kardar,et al. Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies , 2007, Physics in medicine and biology.
[4] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[5] Y. Saad,et al. GMRES: a generalized minimal residual algorithm for solving nonsymmetric linear systems , 1986 .
[6] E. Antonarakis,et al. The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer. , 2012, The Urologic clinics of North America.
[7] Hector Gomez,et al. A Mathematical Model Coupling Tumor Growth and Angiogenesis , 2016, PloS one.
[8] E. Antonarakis,et al. Targeting angiogenesis for the treatment of prostate cancer , 2012, Expert opinion on therapeutic targets.
[9] Ignasi Colominas,et al. Computational Modeling of Tumor-Induced Angiogenesis , 2017, Archives of Computational Methods in Engineering.
[10] Kristin R. Swanson,et al. Toward Patient-Specific, Biologically Optimized Radiation Therapy Plans for the Treatment of Glioblastoma , 2013, PloS one.
[11] H. Gómez,et al. Computational Phase‐Field Modeling , 2017 .
[12] Marek Bodnar,et al. Mathematical and numerical analysis of low-grade gliomas model and the effects of chemotherapy , 2019, Commun. Nonlinear Sci. Numer. Simul..
[13] Viorel Barbu,et al. Nonlinear Differential Equations of Monotone Types in Banach Spaces , 2010 .
[14] Rene Bruno,et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors , 2008, Cancer Chemotherapy and Pharmacology.
[15] Robin T Vollmer,et al. Dissecting the dynamics of serum prostate-specific antigen. , 2010, American journal of clinical pathology.
[16] P. Troncoso,et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] P. Hahnfeldt,et al. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.
[18] Kenneth J. Hillan,et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.
[19] E. Small,et al. Independent association of angiogenesis index with outcome in prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] Thomas E Yankeelov,et al. Predicting the Response of Breast Cancer to Neoadjuvant Therapy Using a Mechanically Coupled Reaction-Diffusion Model. , 2015, Cancer research.
[21] Guillermo Lorenzo,et al. Tissue-scale, personalized modeling and simulation of prostate cancer growth , 2016, Proceedings of the National Academy of Sciences.
[22] H. Garcke,et al. Optimal Control of Treatment Time in a Diffuse Interface Model of Tumor Growth , 2016, 1608.00488.
[23] Jason M. Graham,et al. A spatial model of tumor-host interaction: application of chemotherapy. , 2008, Mathematical biosciences and engineering : MBE.
[24] Vittorio Cristini,et al. Three-dimensional multispecies nonlinear tumor growth-II: Tumor invasion and angiogenesis. , 2010, Journal of theoretical biology.
[25] Bruce J Trock,et al. Application of metabolomics to prostate cancer. , 2011, Urologic oncology.
[26] T. Hughes,et al. Isogeometric analysis : CAD, finite elements, NURBS, exact geometry and mesh refinement , 2005 .
[27] J. Verweij,et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Marcial García-Rojo,et al. Non-standard radiotherapy fractionations delay the time to malignant transformation of low-grade gliomas , 2017, PloS one.
[29] Harald Garcke,et al. A coupled surface-Cahn--Hilliard bulk-diffusion system modeling lipid raft formation in cell membranes , 2015, 1509.03655.
[30] Jyrki Lötjönen,et al. A Comprehensive Panel of Three-Dimensional Models for Studies of Prostate Cancer Growth, Invasion and Drug Responses , 2010, PloS one.
[31] I. Tannock,et al. Chemotherapy-based treatment for castration-resistant prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] P. Kantoff,et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] J. Oden,et al. Selection and Validation of Predictive Models of Radiation Effects on Tumor Growth Based on Noninvasive Imaging Data. , 2017, Computer methods in applied mechanics and engineering.
[34] Triantafyllos Stylianopoulos,et al. The role of mechanical forces in tumor growth and therapy. , 2014, Annual review of biomedical engineering.
[35] P Schucht,et al. A mathematical model of low grade gliomas treated with temozolomide and its therapeutical implications. , 2017, Mathematical biosciences.
[36] P. Maini,et al. Modelling aspects of cancer dynamics: a review , 2006, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.
[37] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[38] W Blumenfeld,et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.
[39] Triantafyllos Stylianopoulos,et al. Role of vascular normalization in benefit from metronomic chemotherapy , 2017, Proceedings of the National Academy of Sciences.
[40] S. Benzekry. Mathematical and numerical analysis of a model for anti-angiogenic therapy in metastatic cancers , 2010, 1009.3173.
[41] J. Lions,et al. Équations Différentielles Opérationnelles Et Problèmes Aux Limites , 1961 .
[42] Elisabetta Rocca,et al. On a diffuse interface model of tumour growth , 2014, European Journal of Applied Mathematics.
[43] Thorsten Schlomm,et al. Prostate cancers in the transition zone: Part 1; pathological aspects , 2004, BJU international.
[44] M. Fraldi,et al. Cells competition in tumor growth poroelasticity , 2018 .
[45] D. Mukherji,et al. Angiogenesis and anti-angiogenic therapy in prostate cancer. , 2013, Critical reviews in oncology/hematology.
[46] O. A. Ladyzhenskai︠a︡,et al. Linear and Quasi-linear Equations of Parabolic Type , 1995 .
[47] H. Frieboes,et al. Three-dimensional multispecies nonlinear tumor growth--I Model and numerical method. , 2008, Journal of theoretical biology.
[48] E. Small,et al. A Phase II Trial of Humanized Anti‐Vascular Endothelial Growth Factor Antibody for the Treatment of Androgen‐Independent Prostate Cancer , 2001 .
[49] R. Sainson,et al. Angiogenesis: an integrative approach from science to medicine , 2008 .
[50] T. Mueller,et al. Monitoring of Xenograft Tumor Growth and Response to Chemotherapy by Non-Invasive In Vivo Multispectral Fluorescence Imaging , 2012, PloS one.
[51] Alicia Martínez-González,et al. Delay effects in the response of low-grade gliomas to radiotherapy: a mathematical model and its therapeutical implications. , 2014, Mathematical medicine and biology : a journal of the IMA.
[52] A. C. M. Resende,et al. A HYBRID THREE-SCALE MODEL OF TUMOR GROWTH. , 2018, Mathematical models & methods in applied sciences : M3AS.
[53] R. Jain,et al. Solid stress generated by spheroid growth estimated using a linear poroelasticity model. , 2003, Microvascular research.
[54] S. Jonathan Chapman,et al. Mathematical Models of Avascular Tumor Growth , 2007, SIAM Rev..
[55] Thomas J. R. Hughes,et al. Hierarchically refined and coarsened splines for moving interface problems, with particular application to phase-field models of prostate tumor growth , 2017 .
[56] P. Hahnfeldt,et al. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. , 2003, Journal of theoretical biology.
[57] J. Lions. Equations Differentielles Operationnelles , 1961 .
[58] Bernhard A. Schrefler,et al. A monolithic multiphase porous medium framework for (a-)vascular tumor growth. , 2018, Computer methods in applied mechanics and engineering.
[59] I. Tannock,et al. Repopulation of cancer cells during therapy: an important cause of treatment failure , 2005, Nature Reviews Cancer.
[60] Zvia Agur,et al. Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model. , 2008, Cancer research.
[61] Philip Hahnfeldt,et al. Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers. , 2013, Journal of theoretical biology.
[62] Harald Garcke,et al. A Cahn–Hilliard–Darcy model for tumour growth with chemotaxis and active transport , 2015, 1508.00437.
[63] Nicola Bellomo,et al. On the foundations of cancer modelling: Selected topics, speculations, and perspectives , 2008 .
[64] Hao-qing Wu,et al. Long-Time Dynamics and Optimal Control of a Diffuse Interface Model for Tumor Growth , 2019, Applied Mathematics & Optimization.
[65] J. Eastham,et al. Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer. , 2015, Urologic oncology.
[66] R W Veltri,et al. Implication of cell kinetic changes during the progression of human prostatic cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[67] J. Murray,et al. A quantitative model for the dynamics of serum prostate-specific antigen as a marker for cancerous growth: an explanation for a medical anomaly. , 2001, The American journal of pathology.
[68] T. Stamey,et al. Assessment of morphometric measurements of prostate carcinoma volume , 2000, Cancer.
[69] W. Oh,et al. Bevacizumab treatment of prostate cancer , 2012, Expert opinion on biological therapy.
[70] H M Byrne,et al. A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy. , 2000, Mathematical biosciences.
[71] J. Sprekels,et al. Optimal distributed control of a diffuse interface model of tumor growth , 2016, 1601.04567.
[72] G Powathil,et al. Mathematical modeling of brain tumors: effects of radiotherapy and chemotherapy , 2007, Physics in medicine and biology.
[73] G. Hulbert,et al. A generalized-α method for integrating the filtered Navier–Stokes equations with a stabilized finite element method , 2000 .
[74] J. Tinsley Oden,et al. GENERAL DIFFUSE-INTERFACE THEORIES AND AN APPROACH TO PREDICTIVE TUMOR GROWTH MODELING , 2010 .
[75] Robert A Gatenby,et al. Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies , 2017, bioRxiv.
[76] A. Miranville,et al. On the long time behavior of a tumor growth model , 2018, Journal of Differential Equations.
[77] G. Sledge,et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[79] Danielle Hilhorst,et al. On a Cahn-Hilliard type phase field system related to tumor growth , 2014, 1401.5943.
[80] E. Small,et al. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate‐resistant prostate cancer , 2011, Cancer.
[81] Thomas E Yankeelov,et al. Clinically Relevant Modeling of Tumor Growth and Treatment Response , 2013, Science Translational Medicine.
[82] V. Quaranta,et al. Integrative mathematical oncology , 2008, Nature Reviews Cancer.
[83] Jintai Chung,et al. A Time Integration Algorithm for Structural Dynamics With Improved Numerical Dissipation: The Generalized-α Method , 1993 .
[84] G. Marinoschi,et al. Sliding Mode Control for a Phase Field System Related to Tumor Growth , 2017, Applied Mathematics & Optimization.
[85] T. Stamey,et al. Observations on the doubling time of prostate cancer. The use of serial prostate‐specific antigen in patients with untreated disease as a measure of increasing cancer volume , 1993, Cancer.
[86] Ming Zhao,et al. Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel , 2004, Clinical Cancer Research.